久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

英國Intercytex?
Intercytex市值約為1,050萬英鎊，該公司目前正在研發一種男性抗脫發藥物。

Intercytex is the leading developer of innovative regenerative medicine products.

Intercytex uses its fully integrated cell technology platform to develop living, human cell-based products, at commercially viable scale in attractive markets.

Intercytex has four products in development:

?

VAVELTA?, a skin repair and rejuvenation product intended to improve the feel, function and appearance of skin damaged by scarring and the aging process, commercially available from a number of accredited centres in the UK

SHEF-1, development of a stem cell line suitable for differentiation into retinal pigment epithelial (RPE) cells, being carried out in collaboration with the London Project to Cure Blindness

ICX-SKN, being developed as a skin graft replacement for burns and acute wounds, Phase I trials completed
ICX-TRC, a hair regeneration product, in Phase II trials.

All Intercytex' products are derived from unmodified human cells.

Intercytex commenced operations in 2000 and currently employs around 50 staff. In addition to its head office in Cambridge, UK, it has its own GMP compliant clinical production facility plus research and development laboratories in Manchester, UK and a dedicated stem cell research laboratory in Sheffield, UK. Additional laboratories are located in Boston, US.

Intercytex’ shares trade on the Alternative Investment Market of the London Stock Exchange under the ticker symbol ICX.L.

?